Identifying “super responders” in pulmonary arterial hypertension
暂无分享,去创建一个
[1] W. Seeger,et al. Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. , 2017, American journal of respiratory and critical care medicine.
[2] J. Newman,et al. Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. , 2016, American journal of respiratory and critical care medicine.
[3] J. Yuan,et al. Genetic Insights into Pulmonary Arterial Hypertension. Application of Whole-Exome Sequencing to the Study of Pathogenic Mechanisms. , 2016, American journal of respiratory and critical care medicine.
[4] Zhongming Zhao,et al. Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. , 2016, American journal of respiratory and critical care medicine.
[5] M. Humbert,et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. , 2016, The Lancet. Respiratory medicine.
[6] R. Gerszten,et al. Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension , 2016, Circulation.
[7] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.
[8] A. Torbicki,et al. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.
[9] J. Loyd,et al. Toward Precision Medicine in Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.
[10] A. Praestgaard,et al. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.
[11] D. Furst,et al. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis–Related Pulmonary Arterial Hypertension , 2015, Arthritis & rheumatology.
[12] R. Benza,et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.
[13] J. Barberà,et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.
[14] H. Ghofrani,et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension , 2015, European Respiratory Journal.
[15] R. Speich,et al. Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension , 2015, Respiration.
[16] A. Hemnes,et al. Fatty Acid Metabolism in Pulmonary Arterial Hypertension: Role in Right Ventricular Dysfunction and Hypertrophy , 2015, Pulmonary circulation.
[17] M. B. Bacchi Reggiani,et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights , 2015, European Respiratory Journal.
[18] David X M Zhao,et al. Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[19] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.
[20] S. Rich,et al. Peripheral Blood Signature of Vasodilator-Responsive Pulmonary Arterial Hypertension , 2015, Circulation.
[21] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[22] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[23] M. Hoeper,et al. The changing landscape of pulmonary arterial hypertension and implications for patient care , 2014, European Respiratory Review.
[24] R. Schermuly,et al. [Relevant issues in the pathology and pathobiology of pulmonary hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[25] J. Marcus,et al. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. , 2014, Chest.
[26] L. Gleaves,et al. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. , 2014, American journal of respiratory and critical care medicine.
[27] H. Ghofrani,et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.
[28] Z. Jing,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[29] Chen Wang,et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. , 2013, The New England journal of medicine.
[30] M. Humbert,et al. Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[31] H. Ghofrani,et al. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study , 2013, Circulation.
[32] J. Newman,et al. Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension. , 2013, JACC. Heart failure.
[33] M. Puhan,et al. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.
[34] M. Clozel,et al. Differential Effects of Selexipag and Prostacyclin Analogs in Rat Pulmonary Artery , 2012, Journal of Pharmacology and Experimental Therapeutics.
[35] Hyuk-Jae Chang,et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[36] H. Morita,et al. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. , 2012, International journal of cardiology.
[37] R. Benza,et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.
[38] N. Voelkel,et al. Pathobiology of pulmonary arterial hypertension and right ventricular failure , 2012, European Respiratory Journal.
[39] Nico Westerhof,et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. , 2011, Journal of the American College of Cardiology.
[40] Matthias Griese,et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.
[41] T. Fleming,et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. , 2011, Chest.
[42] W. Gerthoffer,et al. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. , 2011, American journal of respiratory cell and molecular biology.
[43] J. Fessel,et al. The genetics of pulmonary arterial hypertension in the post-BMPR2 era , 2011, Pulmonary circulation.
[44] H. Palevsky,et al. A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost , 2013, Pulmonary circulation.
[45] D. Hess,et al. Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension , 2011, Pulmonary circulation.
[46] S. Rich,et al. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. , 2010, Chest.
[47] H. Ghofrani,et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. , 2010, American journal of respiratory and critical care medicine.
[48] N. Morrell,et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.
[49] M. Humbert,et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. , 2010, European heart journal.
[50] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.
[51] A. Gemma,et al. F1000 highlights , 2010 .
[52] A. Manes,et al. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses , 2010, European heart journal.
[53] Horst Olschewski,et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. , 2010, Journal of the American College of Cardiology.
[54] M. Humbert,et al. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.
[55] A. Tonelli,et al. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. , 2010, Respiratory medicine.
[56] Horst Olschewski,et al. Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[57] W. Chung,et al. [Genetics and genomics of pulmonary arterial hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[58] B. Brundage,et al. Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.
[59] T. Fleming,et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. , 2008, Annals of internal medicine.
[60] W. Seeger,et al. Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.
[61] R. Benza,et al. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. , 2008, Chest.
[62] S. Rich,et al. A USA-based registry for pulmonary arterial hypertension: 1982–2006 , 2007, European Respiratory Journal.
[63] A. Shorr,et al. Analyzing the short-term effect of placebo therapy in pulmonary arterial hypertension: potential implications for the design of future clinical trials. , 2007, Chest.
[64] J. Loyd,et al. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[65] W. Seeger,et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. , 2006, Journal of the American College of Cardiology.
[66] M. Humbert,et al. Reduced exercise capacity in a mouse model of asthma , 2006, Thorax.
[67] H. Farber,et al. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. , 2006, Annals of internal medicine.
[68] M. Humbert,et al. Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.
[69] R. Benza,et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. , 2006, Chest.
[70] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[71] W. Seeger,et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.
[72] W. Seeger,et al. Imatinib for the treatment of pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[73] D. Badesch,et al. Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.
[74] J. Wharton,et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. , 2005, American journal of respiratory and critical care medicine.
[75] M. Humbert,et al. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.
[76] D. Pennell,et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. , 2005, American journal of respiratory and critical care medicine.
[77] M. Humbert,et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.
[78] D. Mccrory,et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[79] J. Panza,et al. Ethnic Differences in the Vasoconstrictor Activity of Endogenous Endothelin-1 in Hypertensive Patients , 2004, Circulation.
[80] A. Branzi,et al. The endothelin system in pulmonary arterial hypertension. , 2004, Cardiovascular research.
[81] D. Badesch,et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. , 2003, Chest.
[82] P. Arbogast,et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. , 2003, American journal of respiratory and critical care medicine.
[83] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[84] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[85] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[86] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[87] John Arul Phillips,et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. , 2001, The New England journal of medicine.
[88] R. Trembath,et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.
[89] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[90] D. Badesch,et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.
[91] R. Barst,et al. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.
[92] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[93] C. Benjamin,et al. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. , 1995, Molecular pharmacology.
[94] A Giaid,et al. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.
[95] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.
[96] K. Polderman,et al. Influence of Sex Hormones on Plasma Endothelin Levels , 1993, Annals of Internal Medicine.
[97] B. Groves,et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.
[98] S. Rich,et al. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.
[99] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[100] J. H. Diehl,et al. Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .
[101] B. Brundage,et al. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. , 1987, Circulation.
[102] B. Brundage,et al. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. , 1985, Circulation.
[103] B. Massie,et al. Deleterious effects of hydralazine in patients with pulmonary hypertension. , 1982, The New England journal of medicine.
[104] G. Berkenboom,et al. Failure of nifedipine treatment in primary pulmonary hypertension. , 1982, British heart journal.
[105] M. Puhan,et al. Sex differences in response to tadalafil in pulmonary arterial hypertension. , 2015, Chest.
[106] Z. Jing,et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. , 2013, Chest.
[107] H. Palevsky,et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. , 2012, Chest.
[108] G. Raskob,et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. , 2011, Chest.
[109] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .